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The present study was planned to improve the stability of dithranol using solid dispersions (SD). Two 
different SD at a 1:9 ratio of dithranol/excipient were prepared: one of them using glyceryl behenate as 
excipient and the other using a mixture of argan oil with stearic acid (1:8 ratio) as excipient. Pure dithranol 
and SD of dithranol were incorporated in an oil-in-water cream and in a hydrophobic ointment in a drug/
dermatological base ratio of 1:10. The physical and mechanical properties of semisolid formulations 
incorporating the pure drug and the developed SD were evaluated through rheological and textural analysis. 
To evaluate the stability, L*a*b* color space parameters of SD and semisolid formulations, and pH of 
hydrophilic formulations were determined at defined times, during one month. Each sample was stored 
at different conditions namely, light exposure (room temperature), high temperature exposition (37 °C) 
(protected from light) and protected from light (room temperature). Despite higher values of firmness and 
adhesiveness, hydrophobic ointment exhibited the best rheological features compared to the oil-in-water 
cream, namely a shear-thinning behavior and high thixotropy. These formulations have also presented more 
stability, with minor changes in L*a*b* color space parameters. The results of this study indicate that is 
possible to conclude that the developed SD contributed to the increased stability of dithranol.
Uniterms: Dithranol/stability. Topical formulations/development. Solid dispersions/preparation. Stearic 
acid. Glyceryl behenate. Argan oil.
Este trabalho teve como objetivo aumentar a estabalidade do ditranol através da preparação de 
dispersões sólidas (DS). Prepararam-se duas DS diferentes em proporção de 1:9 de ditranol/excipiente: 
em uma das DS utilizou-se beenato de glicerila como excipiente e na outra se utilizou mistura de óleo 
de argan com ácido esteárico (razão 1:8). Posteriormente, efetuou-se a incorporação de ditranol puro 
e das DS contendo este fármaco num creme hidrófilo ou óleo-água (O/A) e em pomada hidrófoba, na 
proporção 1:10 (fármaco ou respetivas DS/base dermatológica). As propriedades físicas e mecânicas das 
formulações semissólidas incorporando fármaco ou as respetivas DS previamente desenvolvidas, foram 
avaliadas através da análise do comportamento reológico e das propriedades de textura. Para avaliar 
a estabilidade, os parâmetros do espaço de cor L*a*b* das DS e das formulações semissólidas e o pH 
das preparações hidrófilas foram determinados em períodos de tempo definidos, durante um mês para 
cada amostra armazenada sob diferentes condições, especificamente, exposição à luz (à temperatura 
ambiente), protegidas da luz à temperatura elevada (37 °C) e protegidas da luz (temperatura ambiente). 
Embora tenham apresentado valores de firmeza e de adesividade mais elevados, as pomadas hidrófobas 
apresentaram melhores características reológicas do que os cremes óleo-água. Além disso, as pomadas 
hidrófobas também apresentaram melhor estabilidade, com pequenas alterações nos parâmetros do espaço 
de cor L*a*b*. Os resultados deste trabalho permitiram concluir que as DS desenvolvidas contribuíram 
para o aumento da estabilidade do ditranol.
Unitermos: Ditranol/estabilidade. Formulações tópicas/desenvolvimento. Dispersões sólidas/preparação. 
Ácido esteárico. Beenato de glicerila. Óleo de argan.
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INTRODUCTION
Psoriasis is a chronic multisystem inflammatory 
disorder with significant co-morbidities and also profound 
physical, emotional and social impacts on quality of life 
(Dvorakova, Markham, 2013). It is clinically characterized 
by erythematous, sharply demarcated papules and rounded 
plaques, covered by silvery scale and epidermal hyper 
proliferation (Christophers, 2001).
Dithranol (1,8-dihydroxy-9-anthrone, anthralin or 
cignolin) is an effective drug for the treatment of chronic 
stable plaque psoriasis and has been used to treat various 
psoriatic disorders for many years (Dvorakova, Markham, 
2013). Despite being effective and safe, its application is 
difficult and troublesome owing to its irritating, burning, 
staining and necrotizing effects on the normal as well 
as the diseased skin. Furthermore, this drug is highly 
lipophilic, poorly water soluble and unstable as it gets 
readily photo-oxidized (Mustakalio, 1981; Wang et al., 
1987).
Dithranol oxidation is enhanced by day light, 
ultraviolet (UV) light, exposure to air and molecular 
oxygen and temperature increase (Mahrle, 1997). This 
drug readily undergoes oxidation to a range of degradation 
products, including danthron and dithranol dimmer, which 
are thought to contribute to the undesired effects and are 
inactive or less active in terms of anti-psoriatic potency 
(Thoma, Holzmann, 1998; Mahrle, 1997). Dithranol has 
a yellow color, while its oxidation products are brown to 
black (Ashton, Andre, Lowe, 1983; Wiegrebe, Plumier, 
Mayer, 1985). So, the color can be a good parameter to 
study the stability of new formulations.
The investigation of the influence of light on the 
stability of drugs has gained importance in recent years. 
For a variety of active substances, a considerable instability 
under the influence of light has been proved (Carlotti et 
al., 2009). Although the semisolid topical formulations are 
protected by their packaging, light-induced degradation 
may occur during production or after application on the 
skin. As dithranol is very unstable, it seemed necessary to 
investigate its behavior under the influence of light and 
temperature (Thoma, Holzmann, 1998).
Various authors have already studied novel 
carriers intended to stabilize dithranol, like solid lipid 
nanoparticles (SLN) prepared by pre-emulsion followed 
by ultrasonication (Gambhire, Bhalekar, Shrivastava, 
2012); phospholipid microemulsion (Raza et al., 2011); 
SLN prepared by solvent injection technique (Carlotti et 
al., 2009) and liposomes (Mahrle et al., 1991).
Solid dispersion (SD) is defined as the dispersion 
of one or more active ingredients in an inert hydrophilic 
carrier or matrix in a solid state, prepared by melting, 
using solvents or by a solvent-melting method (Chiou, 
Riegelman, 1971). Although there is ample use of water 
soluble carriers with no intrinsic solubilizing properties 
such as high molecular weight polyethylene glycols (PEG) 
and polyvinylpyrrolidones (PVP), the use of lipid based 
carriers with solubilizing properties has also attracted 
much interest recently (Serajuddin, 1999). This technique 
allows for reducing particle size to a nearly molecular level 
(Krishnamoorthy, Suchandrasen, Prasad, 2012). Several 
advantages of SD include the uniform and homogeneous 
distribution of small quantities of drug in the solid state, 
the stabilization of unstable drugs, the dispersion of liquid 
or gaseous compounds and the production of prolonged 
release systems (Almeida, Amaral, Lobão, 2012). The 
present study aims to develop solid lipid dispersions 
with dithranol and evaluates drug stability, through 
color evaluation. The stability of two different semisolid 
formulations that incorporate SD was evaluated. Since 
the properties of topical formulations have a major impact 
on patient compliance with treatment (Fouéré, Adjadj, 
Pawin, 2005; Brown, Rehmus, Kimball, 2006; Devaux 
et al., 2012), textural and rheological characterization of 
semisolid formulations were performed.
MATERIAL AND METHODS
Material
Dithranol (Lot. No. 04JP19, Roig Farma, Spain), 
stearic acid (Lot.No. L12020240-OF-5419A, Fagron, 
Spain), argan oil (Lot.No. 121111-P-4, Acofarma, Spain), 
glyceryl behenate (Compritol E ATO) (Lot. No. 108540, 
Gattefossé, France), sodium lauryl sulphate (Lot. No. 
18622400, José M. Vaz Pereira, Portugal), cetyl alcohol 
(Lanette 16) (Lot. No. 5383040010, José M. Vaz Pereira, 
Portugal), white petrolatum (Lot. No. L12120119, 
Fagron, Spain), liquid paraffin (Lot. No. 122403-P-1, 
Acofarma, Spain), glycerin (Lot. No. 12A31-B11-268316, 
Fagron, Spain) and methylparaben (Nipagin M) (Lot. No. 
GB6A039548, José M. Vaz Pereira, Portugal).
Methods
Preparation of solid dispersions containing dithranol
SD at a 1:9 ratio of dithranol/excipient was prepared 
using the fusion method. This ratio was used to make certain 
that all dithranol dissolved in the excipient. Two different 
SDs were prepared, one of them using glyceryl behenate 
(SD C) as excipient and the other using a mixture of argan 
oil with stearic acid (1:8 ratio) as excipient (SD SA).
Use of solid dispersions to increase stability of dithranol in topical formulations 585
Excipient melting (variable temperature according 
to the melting point of the excipients) on a hot plate with 
stirring was used, followed by addition of dithranol to the 
excipient, and then cooled until solidified, when it was 
ground with pestle and mortar.
SDs with particle size less than 180 µm were 
incorporated in an oil-in-water (O/W) cream and in a 
hydrophobic ointment in a drug/dermatological base 
ratio of 1:10, using a mechanical stirrer. Additionally, the 
same formulations with 1% (w/w) of pure dithranol were 
prepared. The qualitative and quantitative composition 
of the different developed formulations is presented in 
Table I.
Preparation of O/W cream and hydrophobic ointment
O/W cream was prepared by heating the aqueous and 
oily phases at 60-70 °C. When the two phases were at the 
same temperature, the aqueous phase was slowly added to 
the oily phase, at a stirring speed of 500-600 rpm. Stirring 
was maintained until cooling.
Hydrophobic ointment was prepared by mechanical 
stirring of white petrolatum with liquid paraffin.
Textural analysis
The textural analysis was performed using a 
texturometer (Stable Micro Systems, TA-XT2i, UK) by 
carrying out a penetration test using a load cell of 5 kg, a 
cylindrical probe with 13 mm diameter (25 mm in the case 
of FD formulation), a penetration depth of 5 mm, a test speed 
of 3 mm/s and a trigger force of 0.049 N. After penetrating 
the sample, the probe returned to a position 50 mm above 
the platform surface. From the obtained graphic force versus 
distance, the maximum force (firmness) and the negative 
area (adhesiveness) were calculated. All the measurements 
were performed in triplicate.
The spreadability was performed using the same 
test; a TTC spreadability probe, a penetration depth of 
23 mm, a test speed of 3 mm/s and a post-test speed of 
10.0 mm/s. In this test, the sample was placed into the 
female cone, avoiding the incorporation of air. The sample 
surface was leveled, the probe was placed at a defined 
position (25 mm) and the assay began with the male cone 
downward (23 mm penetration and 3 mm/s speed), which 
spread the sample between the surfaces of the two cones.
Rheological analysis
Rheological analysis was performed on a rotational 
viscometer HAAKE Viscotester 550 (Thermo Scientific, 
Germany), with a coaxial cylinder sensor SV-DIN. 
The flow behavior was studied by continuous shear 
investigations, which were performed in order to evaluate 
the shear stress (Pa) as a function of shear rate (s-1). The 
study was started with a shear rate of 1 s-1 up to a maximum 
of 500 s-1 and back to 1 s-1, and the resulting shear stress 
was measured. To reduce the influence of temperature 
on the rheological behavior, a thermostatic water bath 
was used to accurately maintain the sample temperature 
(20 °C) during all experiments.
Color evaluation
Since dithranol is a very unstable drug and its 
degradation products confer a formulation change in color, 
the stability of solid dispersions and respective semisolid 
formulations were evaluated by color measurements.
The samples of each semisolid formulation and solid 
dispersion were maintained at different conditions, namely, 
TABLE I – Composition of different formulations with dithranol, SD of dithranol in stearic acid and argan oil (SD SA) and SD 
of dithranol in glyceryl behenate (SD C). FD, FSA and FC corresponds to the O/W cream with pure dithranol, SD SA and SD C, 
respectively; HD, HSA and HC, corresponds to the hydrophobic ointment with pure dithranol, SD SA and SD C, respectively
Composition FD FSA FC HD HSA HC
Dithranol 1 - - 1 - -
SD SA - 10 - 10 -
SD C - - 10 - - 10
Sodium lauryl sulphate 0.99 0.9 0.9 - - -
Cetyl alcohol 8.91 8.1 8.1 - - -
White petrolatum 4.95 4.5 4.5 93.5 85 85
Liquid paraffin 9.9 9.0 9.0 5.5 5 5
Glycerin 9.9 9.0 9.0 - - -
Methylparaben 0.099 0.09 0.09 - - -
Purified water 64.251 58.41 58.41 - - -
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light exposure (at room temperature), high temperature 
exposition (37 °C) (protected from light) and protected 
from light (at room temperature), for one month duration.
L*a*b* color space parameters were determined 
weekly for each sample stored at different conditions, 
using a Minolta CR-400 Chroma meter (Japan) and 
SpectraMagicTM software. Using this device, the sample 
surface is illuminated by a pulsed xenon lamp and the 
light reflected is collected for a tristimulus color analysis 
at 450, 560 and 600 nm, using the L*a*b* color system. 
The L*a*b* system is very comprehensive with the L* 
parameter expressing color brightness (varying between 
100 for a white surface and 0 for a black surface). The 
a* parameter represents changes along a red-green axis 
with changes from +60 for a red surface to -60 to a green 
surface. The b* parameter changes from +60 for yellow 
surface to -60 for a blue surface (Clarys et al., 2000; Zhou 
et al., 2011). The surface measured is 8 mm in diameter. 
The Chroma meter is calibrated using a white calibration 
plate. For each sample, measurements were made in 
triplicate. Color difference (ΔE) is calculated using 
coordinate geometry according to the equation:
	 ∆E = [(∆L*)2 + ∆a*)2 + ∆b*)2]1/2 (1)
pH determination
The pH of semisolid formulations was determined 
weekly in triplicate in each sample stored at different 
conditions, using a Crison Basic 20 pH meter (Spain).
Statistical analysis
The data were statistically analyzed. A Student’s t 
test was performed to understand if the differences were 
significant.
RESULTS AND DISCUSSION
Textural analysis
Figure 1 shows the results of firmness and 
adhesiveness of the different formulations.
The FD results of firmness and adhesiveness 
are not presented in the graphs because the textural 
analysis of this formulation was performed with another 
probe (25 mm), since this sample was more fluid than 
the other formulations. The results of firmness and 
adhesiveness for FD formulation were 0.124 ± 0.002 N 
and -0.716 ± 0.008 N∙mm, respectively. Formulations 
based on hydrophobic ointment had higher firmness and 
adhesiveness values than O/W creams. Additionally, 
formulations containing SD showed higher firmness and 
adhesiveness values than the corresponding formulations 
with pure dithranol. Moreover, formulations with SD of 
glyceryl behenate (SD C) had a small increase in textural 
parameters compared to formulations with SD of stearic 
acid and argan oil (SD SA).
Figure 2 shows the values of spreadability for the 
semisolid formulations. The results were interpreted as 
the difficulty of spreading, as the smaller the maximum 
positive force, the easier the spreading (Savary, Grisel, 
Picard, 2013). The formulation for which it was necessary 
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FIGURE 1 – Results of firmness and adhesiveness of the 
formulations containing dithranol (HD) and solid dispersions 
of dithranol in stearic acid and argan oil (FSA and HSA) and in 
glyceryl behenate (FC and HC).
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FIGURE 2 – Spreadability (Maximum force in N) of the 
formulations containing dithranol (FD and HD) and solid 
dispersions of dithranol in stearic acid and argan oil (FSA and 
HSA) and in glyceryl behenate (FC and HC).
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to apply a smaller force to spread was the O/W cream FD, 
whereas, hydrophobic ointments HSA and HC required the 
greatest forces to spread.
Formulations with pure dithranol were easier to 
spread than formulations containing solid dispersions. 
However, there were not considerable differences between 
formulations with SD SA (FSA and FC) and with SD C 
(HSA and HC).
Rheological analysis
Figure 3 depicts the plots of the shear stress as a 
function of shear rate of the semisolid formulations.
The flow curves of the tested formulations revealed a 
non-Newtonian shear-thinning behavior, with yield value. 
The yield value, i.e. the stress above which the structure 
of the system is broken down, is greater in hydrophobic 
ointments HD, HSA and HC than in oil-in-water creams. 
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FIGURE 3 – Shear stress as a function of the shear rate of 
the semisolid formulations. Upper and lower curves present 
ascending and descending measurements, respectively, for each 
formulation.
These systems start flowing after achieving a yield value 
and the viscosity of the formulations decrease with 
increasing shear rate. As it was observed in the studies of 
Gilbert et al., the formulations with higher yield values 
showed higher values of viscosity and shear stress than the 
other formulations (Gilbert et al., 2013). The rheograms 
of FSA and FC are not shown, because there was been a 
lack of uniformity in the obtained results.
Thixotropy, a reversible variation of viscosity with 
time, was observed in all formulations, demonstrated 
by the presence of hysteresis area between ascending 
and descending curves of the rheograms. This feature is 
desirable in topical formulations, since it could facilitate 
the application of the product on the skin surface (Silva et 
al., 2012; Korhonen et al., 2001). Regarding the hysteresis 
area, this was greater in the case of formulations HD, HSA, 
HC and also FC.
The knowledge about mechanical properties of 
topical formulations, with special emphasis on rheology, 
is useful because the information can be used as a 
technological tool to predict their spreading capacity on 
the skin (Van de Kerkof et al., 2002).
In a study performed by Marty and co-workers, in 
which the rheological characterization of topical ointments 
used in psoriasis treatment were compared with the 
consumer acceptability, it was found that the formulation 
with optimal rheological characteristics (shear-thinning) 
is also preferred by psoriatic patients (Marty et al., 2005).
Color evaluation
The ΔE, determined according to equation 1, 
for samples at different times, stored under different 
conditions are shown in Table II.
A change or difference in color corresponding to a 
value of ΔE>1.5 can be perceived by the human eye (Stark 
et al., 1996). The significant differences observed were 
correlated with the ΔE greater than 1.5. With the exception 
of SD SA, all samples presented values of ΔE greater than 
1.5 and showed an increase of this parameter over time. 
All formulations with pure dithranol showed greater ΔE 
values than semisolid formulations with SD containing 
dithranol. Considering the different SD, in general, SD 
SA and formulations with SD SA showed more stability 
than SD C and formulations containing this SD. In the 
majority of cases, the values of ΔE obtained each week for 
SD SA and their semisolid formulations were lower than 
the results of ΔE values of SD C and their formulations, 
with the exception of HSA at 37 °C.
Comparing O/W cream with hydrophobic ointment, 
it can be concluded that the latter conferred more stability 
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may arise due to decomposition of excipients or due to 
interaction between drug and excipients (Stark et al., 1996).
Thoma and Holzmann investigated the photostability 
of dithranol 0.1% (w/w) in various solvents and excipients 
and have shown that in macrogol 400 (hydrophilic 
excipient), the drug is already unstable without irradiation 
and the influence of light plays only a minor role for the 
degradation reaction. However, in a paraffin base, that 
offers high stability for dithranol under the exclusion of 
light, a distinct instability exists under the influence of 
light (Thoma, Holzmann, 1998).
It is possible to observe that in some cases (FC, HSA 
and HD) the temperature affects the ΔE values more so 
than the light. Previous results obtained by other authors 
demonstrate that various formulations containing dithranol 
were more stable at refrigerated conditions (5 ± 3 °C) than 
the same formulations stored at 45 ± 2 °C (Raza et al., 2011).
There was a correlation between color and time 
for FD (dark/room temperature) and FSA (dark/room 
temperature) where linear regressions of ΔE versus 
time (weeks) were: y = 9.75x + 0.06; R2 = 0.99 and 
y = 4.13x – 0.1; R2 = 0.99; respectively.
Considering CIEL*a*b* color space parameters, 
it is possible to conclude that dithranol degradation 
corresponds to a significant increase in a* value and a 
decrease in L* and b* parameters. The formulation where 
this observation was more pronounced was FD, which 
gained a brown color with time.
Rhee et al., have observed that the change in color 
value in a formulation of rabeprazole as measured by the 
total difference ΔE showed an exponential relationship 
with drug degradation products, which suggested that color 
changes could be detected before chemical degradation 
amassed to a noticeable extent (Rhee et al., 2008).
pH determination of O/W formulations
Table III shows the pH values of each semisolid 
formulation.
The formulation containing SD SA (FSA) showed 
lower pH variations than the other formulations, which 
suffered significant pH variations with time. The 
formulations FD, FSA and FC stored at 37 °C during 
four weeks suffered the highest pH variation. The pH 
of FSA (dark/room temperature) and FSA (light/room 
temperature) remained more stable than the formulations 
with pure dithranol and SD C. Since the dermatological 
base is the same, we can presume that the observed 
differences are due to the fact that preparations contain 
pure dithranol or SD, instead of eventual alterations in 
the O/W cream constituents. Some authors have already 
TABLE II – Color testing results (ΔE values) of samples at 
different times stored under different conditions, determined 
weekly during one month
Time 
(Weeks) SD SA (dark) SD SA (light) SD SA (37 °C)
1 0.2 1.9 0.6
2 0.6 1.9 1.4
3 0.6 2.1 1.1
4 0.7 2.5 1.3
SD C (dark) SD C (light) SD C (37 °C)
1 0.7 1.3 3.0
2 1.2 2.3 5,0
3 1.7 2.7 5.2
4 2.0 4.2 6.9
FD (dark) FD (light) FD (37 °C)
1 8.4 8.9 27.5
2 21.7 26.1 32.3
3 29.5 32.6 36.8
4 38.2 40.6 40.7
HD (dark) HD (light) HD (37 °C)
1 5.0 5.9 7.3
2 6.0 6.7 8.9
3 6.4 7.4 9.3
4 6.5 7.7 9.6
FSA (dark) FSA (light) FSA (37 °C)
1 3.8 8.5 2.7
2 8.2 15.9 7.3
3 12.5 20.3 14.6
4 16.3 24.1 22.0
HSA (dark) HSA (light) HSA (37 °C)
1 4.3 5.2 5.5
2 4.8 5.6 8.0
3 5.0 5.8 8.4
4 5.2 6.2 6.4
FC (dark) FC (light) FC (37 °C)
1 8.7 8.7 14.4
2 17.1 17.4 23.1
3 22.9 23.0 29.1
4 26.4 28.0 36.2
HC (dark) HC (light) HC (37 °C)
1 3.8 6.6 5.2
2 4.9 9.2 5.5
3 6.5 11.4 5.9
4 7.9 11.5 5.6
since the ΔE values were lower than those obtained with 
the emulsified dermatological base. This can be due to 
the presence of water in the cream. Even when color 
change correlates with drug decomposition, this does 
not necessarily imply a causal relationship. Indeed color 
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TABLE III – pH values of samples at time 0 and after 4 weeks of storage under different conditions and pH differences
0 4 Δ pH
FD – dark/room temperature 6.62 ± 0.16 4.42 ± 0.20 -2.20 ± 0.36
FD – light/room temperature 6.63 ± 0.08 5.51 ± 0.38 -1.12 ± 0.62
FD – 37 ºC 6.58 ± 0.20 4.01 ± 0.56 -2.57 ± 0.41
FSA – dark/room temperature 4.44 ± 0.05 4.69 ± 0.23 0.26 ± 0.19
FSA – light/room temperature 4.61 ± 0.17 4.57 ± 0.22 -0.04 ± 0.11
FSA – 37 ºC 4.73 ± 0.25 2.61 ± 0.23 -2.12 ± 0.12
FC – dark/room temperature 5.74 ± 0.06 4.42 ± 0.24 -1.33 ± 0.27
FC – light/room temperature 5.73 ± 0.04 4.32 ± 0.07 -1.41 ± 0.09
FC – 37 ºC 5.86 ± 0.15 2.76 ± 0.16 -3.11 ± 0.22
related pH changes during storage with chemical stability. 
Dragicevic-Curic et al. developed liposomal hydrogels and 
the pH value and drug content was determined after their 
preparation and at predetermined time intervals during 6 
months of storage at 4 and 23 °C. The drug content and pH 
values did not show remarkable changes during the storage 
of gels, which indicate chemical stability during storage at 
both temperatures (Dragicevic-Curic et al., 2010).
CONCLUSIONS
It was possible to conclude that SD increases the 
stability of dithranol, and that an SD of stearic acid with 
argan oil (SD SA) achieves this purpose better than an SD of 
glyceryl behenate (SD C). However, the dermatological base 
also influences the stability, and the anhydrous formulations 
(hydrophobic ointment) showed the best results compared 
to the formulations containing water in their composition. In 
the future it will be important to optimize the dermatological 
base for SD incorporation, for example, with the addition of 
an antioxidant to obtain a completely stable system, suitable 
for skin application of dithranol.
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